Pediatric Self-Assessment Program (PEDSAP) 2026 (L269116)
ACPE Numbers: Various – see listing below Release Date: July 15, 2026 Expiration Dates: July 15, 2027 Activity Type: Application-based CE Credits: 20.5 contact hours (BPS and ACPE) Activity Fee: $88 (ASHP member); $132 (non-member)
Activity Overview
This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 9 learning modules (see table below) and provides up to 20.5 contact hours of continuing pharmacy education and/or recertification credit.
Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ACCP and ASHP professional development program for BCPPS recertification approved by the BPS.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.
Board certified pharmacists are eligible to receive up to 20.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
ACCP and ASHP are approved by BPS as a provider for the recertification of BCPPS.
Learning Activity
Passing Score
Credit Information
Skin and Soft Tissue Infections
73%
2.0 Contact Hours
BPS: BCPPS ACPE: 0217-9999-26-173-H01-P
Novel Antiseizure Medications
60%
2.5 Contact Hours
BPS: BCPPS ACPE: 0217-9999-26-174-H01-P
Pediatric Hypertension
66%
3.0 Contact Hours
BPS: BCPPS ACPE: 0217-9999-26-175-H01-P
Anemia of the Pediatric Patient
66%
3.0 Contact Hours
BPS: BCPPS ACPE: 0217-9999-26-176-H01-P
Growth Hormone Therapy
66%
1.5 Contact Hours
BPS: BCPPS ACPE: 0217-9999-26-177-H01-P
Inflammatory Bowel Disease
66%
3.0 Contact Hours
BPS: BCPPS ACPE: 0217-9999-26-178-H01-P
Case Series: Pediatric Palliative and Hospice Care
Chapter: Skin and Soft Tissue Infections ACPE #: 0217-9999-26-173-H01-P
Demonstrate an understanding of the pathophysiology of skin and soft tissue infections (SSTIs) and the complications associated with SSTIs in pediatric patients.
Assess the bacterial etiologies and risk factors associated with SSTIs in pediatric patients.
Assess common pediatric bacterial SSTIs based on clinical presentation.
Evaluate diagnostic strategies for SSTIs in children, including indications for obtaining cultures and imaging.
Develop evidence-based pharmacologic and nonpharmacologic treatment plans, emphasizing empiric antibiotic selection, dosing, route of administration, and duration for various bacterial SSTIs.
Design pediatric patient–specific treatment plans based on patient-specific factors that influence antibiotic regimen selection (eg, age, antibiotic allergy history, pathogen identified) for SSTIs.
Evaluate the recent updates and expanded indications used in pediatric SSTIs.
Apply the principles of rational polypharmacy including, but not limited to, its associated challenges when developing treatment regimens for pediatric patients with epilepsy.
Evaluate the role of novel therapeutic and abortive antiseizure medications (ASMs) in the treatment regimens of pediatric patients with epilepsy.
Distinguish between the basic principles of precision medicine (PM) and emerging molecular and gene therapies for pediatric patients with epilepsy.
Distinguish incidence and common etiology of hypertension (HTN) in the pediatric population.
Analyze and apply appropriate lifestyle and nonpharmacologic interventions for pediatric HTN.
Analyze and apply appropriate pharmacologic treatment options for pediatric HTN unresponsive to lifestyle modifications and nonpharmacologic interventions.
Distinguish differences between early and older-onset inflammatory bowel disease (IBD).
Evaluate evidence surrounding conventional therapies for children with IBD.
Analyze available data on biologics and small-molecule inhibitors for pediatric IBD.
Design a monitoring and treatment plan for a child with IBD based on patient-specific factors and risk-benefit assessment.
Devise supportive care medication strategies to mitigate IBD-sequelae and treatment-related adverse effects.
Case Series: Pediatric Palliative and Hospice Care ACPE #: 0217-9999-26-179-H08-P
Develop an appropriate care plan for a patient with a life-limiting condition.
Evaluate care plan to align with patient-specific goals of care.
Design an appropriate symptom management plan for a pediatric palliative care patient.
Assess medication appropriateness as patients approach end of life.
Case Series: Updates in Cystic Fibrosis ACPE #: 0217-9999-26-180-H01-P
Analyze available cystic fibrosis transmembrane regulator (CFTR) modulator therapies, including associated benefits, adverse effects, and impacts on overall disease management.
Evaluate the impacts of CFTR modulator therapies on other aspects of disease management.
Design an appropriate therapeutic plan for treatment of a pediatric patient with a CF exacerbation.
Case Series: Pregnancy Emergencies ACPE #: 0217-9999-26-181-H01-P
Apply strategies for mitigating potential medication safety issues when treating pregnancy emergencies.
Evaluate the appropriateness of a medication regimen for an obstetric emergency on the basis of current evidence and recommendations.
Design an effective therapeutic plan for a pregnant or postpartum patient with an obstetric emergency.
Assess the risk of neonatal effects from pharmacotherapy used during pregnancy emergencies.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP require that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Consultancies:Brittany A. Rodriguez (bioMerieux), Astrela Moore (Sobi), Cameron J. McKinzie (Vertex Pharmaceuticals)
Stock Ownership: Courtney Kain (Pfizer, Bristol Myers Squibb, Medtronic)
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
Complete the attestation statement
Review all content
Complete and pass the assessments
Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
